Patents by Inventor Bruce SCHNEPP

Bruce SCHNEPP has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240092885
    Abstract: The present disclosure provides gene therapy expression constructs comprising a nucleic acid encoding a therapeutic anti-TNFalpha antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof, delivery vectors (e.g., viral vectors) comprising the same, compositions comprising the same, and methods of using the same (e.g., to treat ocular diseases or disorders). Some aspects of the disclosure are directed to a recombinant adeno-viral vector (rAAV) delivery comprising an AAV particle (e.g., AAV2) and a nucleic acid encoding a therapeutic anti-TNFalpha antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof.
    Type: Application
    Filed: January 26, 2022
    Publication date: March 21, 2024
    Inventors: Brian FURMANSKI, Bruce SCHNEPP, Nachi GUPTA, Shankar RAMASWAMY, Weiran SHEN
  • Publication number: 20230295332
    Abstract: Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.
    Type: Application
    Filed: December 15, 2022
    Publication date: September 21, 2023
    Inventors: Ronnie M. Russell, Philip R. Johnson, James I. Andorko, Mohit Sachdeva, Bruce Schnepp, Michael Marinelli, Jeffrey Foss, Debasish Boral
  • Publication number: 20230293688
    Abstract: Provided for herein are fusogenic rhabdovirus glycoproteins and uses thereof, compositions comprising the same, and methods of using the same. Also provided for herein are pseudotyped viral particles comprising rhabdovirus glycoproteins as provided for herein and targeting moieties as provided for herein. Also provided are methods of generating and using the pseudotyped viral particles as provided for herein.
    Type: Application
    Filed: February 10, 2023
    Publication date: September 21, 2023
    Inventors: Ronnie M. Russell, Bruce Schnepp, James I. Andorko, Michael Marinelli, Mohit Sachdeva, Debasish Boral, Jeffery Foss
  • Publication number: 20230279363
    Abstract: Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.
    Type: Application
    Filed: January 20, 2023
    Publication date: September 7, 2023
    Inventors: Ronnie M. Russell, Philip R. Johnson, James I. Andorko, Mohit Sachdeva, Bruce Schnepp, Michael Marinelli, Jeffrey Foss, Debasish Boral
  • Publication number: 20220162638
    Abstract: The present disclosure provides the gene therapy compositions comprising vectors (e.g., viral vectors) suitable for delivery of nucleic acids encoding immunomodulatory proteins or functional fragments thereof, and methods of using the same. Certain aspects of the disclosure are directed to an adeno-viral vector (AAV) delivery of nucleic acids encoding two or more immunomodulatory proteins or functional fragments thereof to a tumor.
    Type: Application
    Filed: October 13, 2021
    Publication date: May 26, 2022
    Inventors: Brian FURMANSKI, Nachi GUPTA, Bruce SCHNEPP, Michele STONE